Global GLP-1 Drug Supply, Demand and Key Producers, 2023-2029

Global GLP-1 Drug Supply, Demand and Key Producers, 2023-2029

The global GLP-1 Drug market size is expected to reach $ 98000 million by 2029, rising at a market growth of 24.6% CAGR during the forecast period (2023-2029).

This report studies the global GLP-1 Drug production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for GLP-1 Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global GLP-1 Drug total production and demand, 2018-2029, (K Units)

Global GLP-1 Drug total production value, 2018-2029, (USD Million)

Global GLP-1 Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global GLP-1 Drug consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: GLP-1 Drug domestic production, consumption, key domestic manufacturers and share

Global GLP-1 Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global GLP-1 Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global GLP-1 Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global GLP-1 Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, AstraZeneca, Sanofi, Pfizer Inc, Novo Nordisk, Boehringer Ingelheim, GlaxoSmithKline (GSK), East China Pharmaceutical Co., Ltd. and Gan & Lee Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global GLP-1 Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global GLP-1 Drug Market, Segmentation by Type
Short-acting GLP-1 Drug
Long-acting GLP-1 Drug

Global GLP-1 Drug Market, Segmentation by Application
Obesity
Type 2 Diabetes (T2DM)
Cardiovascular and Cerebrovascular Diseases (CVD)
Non-alcoholic Steatohepatitis (NASH)
Alzheimer's Disease (AD)

Companies Profiled:
Eli Lilly
AstraZeneca
Sanofi
Pfizer Inc
Novo Nordisk
Boehringer Ingelheim
GlaxoSmithKline (GSK)
East China Pharmaceutical Co., Ltd.
Gan & Lee Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Key Questions Answered

1. How big is the global GLP-1 Drug market?

2. What is the demand of the global GLP-1 Drug market?

3. What is the year over year growth of the global GLP-1 Drug market?

4. What is the production and production value of the global GLP-1 Drug market?

5. Who are the key producers in the global GLP-1 Drug market?